Dynepo

Procedural steps taken and scientific information after the authorisation

MAJOR CHANGES[1]

No	Scope	Opinion issued on	Commission Decision Issued/ amended on	Product Information affected[2]	Summary
II/0020	Update of Summary of Product Characteristics, Labelling and Package Leaflet	24/01/2008	29/02/2008	SPC, Labelling, PL	This variation primarily concerns an update of the SPC following the completion of a class safety review by the PhVWP and the CHMP. The safety review was initiated because recent data show a consistent unexplained excess mortality in cancer patients with anaemia treated with epoetins, and that treatment of anaemia with epoetins in patients with chronic kidney disease to achieve relatively high target haemoglobin concentrations may be associated with an increase in the risk of mortality and cardiovascular morbidity. As a result, the main changes being implemented are: i) in section 4.1, to highlight that epoetins should be used only if associated with symptoms, ii) in Section 4.2 to establish a uniform target haemoglobin range for all epoetins, iii) in Section 4.4 to mention the observed negative benefit risk balance in patients treated with high target haemoglobin concentrations, and to remove safety statements that are relevant only for the treatment of anaemia associated with cancer, and iv) in section 5.1 to include the relevant results of the trials triggering the safety review. The package leaflet has been updated accordingly Additionally, sections 4.8 and 6.6 have also been amended to correct minor inconsistencies, as have the package leaflet and labelling.
II/0019	Change(s) to the manufacturing process for the finished product	21/02/2008	03/03/2008		
II/0014	Change to the test procedure and/or specification of a starting material	21/06/2007	24/07/2007		
II/0010	New presentation(s)	22/02/2007	02/04/2007	SPC, Labelling, PL	
R/0009	Renewal of the Marketing Authorisation	22/02/2007	17/04/2007	SPC, Annex II,	Based upon the data that have become available since the granting of

[1] Major changes e.g. Type II variations, Annex II applications, Renewals and Annual Reassessments
[2] SPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet)

©EMEA 2008

Medicinal product no longer authorised

No	Scope	Opinion issued on	Commission Decision Issued/ amended on	Product Information affected[2]	Summary
				Labelling, PL	the initial Marketing Authorisation, the CHMP considers that the benefit/risk balance of Dynepo remains positive, but considers that its safety profile is to be closely monitored for the following reasons: Dynepo was authorised in the EU on 18 March 2002. However, the medicinal product was not yet launched on the European market as well as on any other market worldwide. Therefore, post-marketing experience in the EU and worldwide is not available at the time of this renewal. The only available safety data was collected from clinical trials. These data are limited and cannot be used to assess post marketing safety of Dynepo. Moreover, data on long-term exposure to Dynepo is limited. Although there have been no significant safety concerns highlighted, the CHMP considers the available safety data not sufficient to support a renewal with unlimited validity. The CHMP decided that Dynepo should not be renewed with unlimited validity at this point. The MAH will therefore be required to submit one additional five-year renewal, in line with the requirements of current legislation.
II/0007	Change(s) to the manufacturing process for the finished product	21/09/2006	23/10/2006	Annex II, PL	
II/0006	Change(s) to the test method(s) and/or specifications for the finished product	21/09/2006	23/10/2006	SPC, PL	
II/0005	Change(s) to the test method(s) and/or specifications for the active substance	21/09/2006	25/09/2006		
II/0004	Change(s) to the manufacturing process for the active substance	21/09/2006	23/10/2006	Annex II	
II/0003	Update of Summary of Product Characteristics, Labelling and Package Leaflet	27/04/2006	08/06/2006	SPC, Annex II, Labelling, PL	Update of Summary of Product Characteristics, Labelling and Package Leaflet following PhVWP assessment of the risk of tumour growth progression and thromoembolic events in cancer patients. Sections requested to update were 4.2, 4.4 and 5.1.
T/0001	Transfer of Marketing Authorisation Holder	10/08/2005	13/09/2005	SPC, Labelling, PL	

Medicinal product no longer authorised

©EMEA 2008

MINOR CHANGES[3]

No	Scope	Product Information affected[2]	Date[4]
IB/0022	12_a_Change in spec. of active subst./agent used in manuf. of active subst. - tightening 37_a_Change in the specification of the finished product - tightening of specification limits		28/01/2008
IB/0021	12_a_Change in spec. of active subst./agent used in manuf. of active subst. - tightening		28/01/2008
IA/0017	08_b_01_Change in BR/QC testing - repl./add. manuf. responsible for BR - not incl. BC/testing	Annex II, PL	05/06/2007
N/0013	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	PL	16/03/2007
IA/0012	07_a_Replacement/add. of manufacturing site: Secondary packaging site		18/01/2007
IA/0011	05_Change in the name and/or address of a manufacturer of the finished product	Annex II, PL	07/12/2006
N/0008	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	Labelling, PL	04/09/2006
IA/0002	47_a_Deletion of a pharmaceutical form	SPC, Labelling, PL	27/10/2005

Medicinal product no longer authorised

[3] Minor changes e.g. Type I variations and Notifications
[4] Date of entry into force of the change

©EMEA 2008